In a groundbreaking study published in Nature Cell Biology, researchers from the Rudolf Virchow Centre (RVZ) at Julius-Maximilians-Universität Würzburg (JMU) have uncovered a surprising and critical role played by vitamin B2, or riboflavin, in cancer cell survival. This study sheds light on how riboflavin metabolism contributes to the resistance of cancer cells to a specific and highly regulated form of cell death known as ferroptosis. The findings open new avenues for therapeutic strategies targeting this vitamin’s metabolic pathway to combat cancer more effectively.
Riboflavin, an essential micronutrient that humans cannot synthesize, must be obtained through dietary sources such as dairy, eggs, meat, and green vegetables. Once absorbed, the vitamin is metabolized into active cofactors that protect cellular components from oxidative damage. While this protective function is beneficial for maintaining healthy cell integrity, the team at RVZ has demonstrated that the same mechanisms also shield malignant cells, enabling their survival under conditions that would typically induce cell death.
Ferroptosis differs fundamentally from other forms of programmed cell death like apoptosis or necrosis. It is triggered by an accumulation of iron-dependent lipid peroxides, which leads to catastrophic membrane damage and ultimately the demise of the affected cell. This process has emerged as a pivotal biological mechanism not only in cancer but also in various neurodegenerative diseases and tissue injuries. The central mystery has been understanding how cancer cells circumvent ferroptosis to persist and proliferate uncontrollably.
The study highlights the role of FSP1 (ferroptosis suppressor protein 1), a critical enzyme that mitigates ferroptosis by maintaining antioxidant defenses inside the cell. Riboflavin-derived cofactors are indispensable for the enzymatic functions of FSP1, meaning that vitamin B2 metabolism is directly linked to the cancer cell’s ability to dodge ferroptotic death. Using advanced genome editing tools and cellular models, the researchers observed that disrupting riboflavin metabolism sensitized cancer cells to ferroptosis, thereby undermining their survival advantage.
This finding suggests that targeting the riboflavin metabolic pathway might represent a novel and effective strategy to selectively induce ferroptosis in cancer cells without affecting normal cells. Despite this potential, a significant challenge remains: no specific inhibitors of the metabolic enzymes involved in vitamin B2 processing have yet been identified or developed for clinical use.
To overcome this barrier, the research team explored the use of roseoflavin, a naturally occurring analog of riboflavin produced by certain bacteria. Roseoflavin mimics vitamin B2 but can interfere with its metabolic functions. Laboratory experiments demonstrated that roseoflavin, even at low concentrations, could trigger ferroptosis in cancer cells. This exciting result provides proof of concept that metabolic inhibition of riboflavin-dependent pathways can be harnessed to provoke ferroptotic cell death selectively, thereby laying the groundwork for future cancer therapies based on ferroptosis induction.
Looking ahead, the researchers are focused on refining and developing more potent and selective inhibitors of the riboflavin metabolic machinery. These next-generation molecules will be evaluated in preclinical models to assess their therapeutic efficacy and safety profile. Such developments could mark a paradigm shift in oncological treatment, especially for tumors that have developed resistance to conventional therapies.
Professor José Pedro Friedmann Angeli, leader of the research group, emphasized the broader implications of their findings. “Ferroptosis is not just critical in cancer biology but is increasingly recognized as a contributing factor in diverse pathological conditions, including neurodegeneration, ischemia-reperfusion injury, and post-transplant tissue damage,” he explained. Thus, an improved understanding of how vitamin B2 metabolism influences ferroptosis could also have significant repercussions in treating a variety of diseases beyond oncology.
The mechanistic insights gained from this study underscore the complex interplay between micronutrient metabolism and cell death regulation, enriching our molecular understanding of tumor biology. This intersection of metabolism and cell fate decisions represents a fertile ground for discovering biomarkers that can predict response to ferroptosis-based therapies as well as for the development of combination treatments that sensitize tumors to iron-dependent oxidative stress.
The study’s funding was provided by the German Research Foundation’s priority programme SPP2306, dedicated to ferroptosis research from molecular basics to clinical applications. Additionally, significant support came from the DeciFerr project, led by Professor Friedmann Angeli and backed by the European Research Council through an ERC Consolidator Grant awarded in May 2024. This robust financial backing highlights the recognized importance and cutting-edge nature of the work in this emerging field.
While the immediate focus remains on exploiting the riboflavin-FSP1 axis to combat cancer, ongoing research may unlock further therapeutic windows for managing neurodegenerative diseases such as Alzheimer’s and Parkinson’s, where ferroptotic mechanisms contribute to neuronal loss. The possibility of modulating ferroptosis bi-directionally—either enhancing it to kill cancer cells or suppressing it to preserve vulnerable neurons—illustrates the transformative potential of understanding this metabolic pathway in unprecedented detail.
As research progresses, the discovery that a simple vitamin like B2, commonly taken for granted as a dietary supplement, is intricately woven into the fundamental processes governing cell death resistance challenges previous assumptions. It invites clinicians, biochemists, and pharmacologists alike to re-examine the role of metabolism in cancer and develop new therapeutic paradigms to improve patient outcomes worldwide.
Subject of Research: Cells
Article Title: Riboflavin metabolism shapes FSP1-driven ferroptosis resistance
News Publication Date: 13-Mar-2026
Web References: http://dx.doi.org/10.1038/s41556-025-01856-x
References: Skafar et al., Riboflavin metabolism shapes FSP1-driven ferroptosis resistance, Nature Cell Biology, 2026
Image Credits: University of Würzburg / Rudolf Virchow Centre
Keywords: vitamin B2, riboflavin metabolism, ferroptosis, cancer therapy, programmed cell death, FSP1, roseoflavin, oxidative stress, lipid peroxidation, cancer resistance, translational cell biology, ferroptosis inhibitor
